Ellsworth Advisors LLC Acquires 1,719 Shares of Eli Lilly and Company $LLY

Ellsworth Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 66.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,301 shares of the company’s stock after acquiring an additional 1,719 shares during the period. Ellsworth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,555,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Trexquant Investment LP raised its stake in Eli Lilly and Company by 208.1% during the first quarter. Trexquant Investment LP now owns 13,619 shares of the company’s stock worth $11,248,000 after acquiring an additional 9,198 shares in the last quarter. Driehaus Capital Management LLC raised its stake in Eli Lilly and Company by 73.2% during the first quarter. Driehaus Capital Management LLC now owns 1,675 shares of the company’s stock worth $1,383,000 after acquiring an additional 708 shares in the last quarter. Finally, Activest Wealth Management lifted its holdings in shares of Eli Lilly and Company by 101.8% during the first quarter. Activest Wealth Management now owns 230 shares of the company’s stock valued at $190,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.0%

Shares of NYSE LLY opened at $1,077.26 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a 50-day moving average of $986.75 and a two-hundred day moving average of $841.37. The company has a market cap of $1.02 trillion, a PE ratio of 52.70, a P/E/G ratio of 1.09 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the business posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, December 16th. CICC Research raised their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Guggenheim reiterated a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Finally, Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.